etrials Chosen by MacuSight as its EDC and IVR Solutions Provider On Three Ophthalmology Studies

etrials Worldwide, Inc. (NASDAQ:ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, announced today that MacuSight Inc., has selected etrials� Trial Intelligence electronic data capture (EDC) and etrials� Site Intelligence IVR solutions as the central component of its clinical data management process, playing a key role in helping MacuSight to glean actionable information from its clinical trial data, thereby enhancing and accelerating decision-making.

"The quality of data and the ability to complete a thorough data analysis are critical success factors for any clinical study. etrials� Trial Intelligence EDC solution affords us rapid and accurate data collection, and offers the ability to integrate pertinent IVR data into EDC in real-time," said Joel Naor, M.D., MacuSight�s Chief Medical Officer. �Every opportunity to improve data collection efficiencies moves us that much closer to bringing these important new ophthalmology therapies to market.�

MacuSight Inc., a privately-held pharmaceutical company based in Union City, California, focuses on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye.

"In these times of serious economic scrutiny, the pressure on companies like MacuSight to produce innovative products in a cost-efficient manner has never been greater,� said M. Denis Connaghan, CEO and president of etrials. �It�s about working smarter and our eClinical solutions deliver significant time and costs savings with greater access to actionable information. We are proud to be involved in MacuSight�s efforts to develop these novel treatments.�

After a formal evaluation of several eClinical vendors, the MacuSight team selected the etrials Trial Intelligence EDC and IVR solutions for not only their best-of-breed functionality, but also their nimble and experienced client teams who would be implementing these systems as an integral component in the MacuSight studies� data management, enrollment and randomization efforts.

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates. For more information, visit www.macusight.com.

About etrials(R)

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of eClinical software and services to pharmaceutical, biotechnology, medical device and contract research organizations, offers adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management � turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the only top-tier solution providers that offers electronic data capture (EDC), interactive voice and Web response (IVR/IWR), electronic patient diaries (eDiary) as part of a flexible and integrated software-as-a-service (SaaS) platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for perfectly informed decision-making. As an experienced leader, etrials has facilitated over 900 trials involving more than 450,000 patients in 70 countries, and has participated in 42 studies that resulted in 14 approved new drug applications and/or regulatory approvals. To learn more visit us at www.etrials.com. etwcf

Forward-Looking Statements

This announcement may contain forward-looking statements, including statements regarding the size, number of sites and patients, new projects, modifications to existing projects, and duration of clinical trial projects awarded to the Company. These statements involve risks and uncertainties. Actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, the need to finalize definitive agreements for the awards, delays in the current schedule for clinical trials by the client, utilization of our software and services by clients to a lesser degree than is currently expected and early termination of the projects, all of which are possible because our agreements do not generally have minimum volume guarantees and can be terminated without penalty by clients. More information about potential factors which could cause actual results to differ from the forward-looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 10-K filed on March 10, 2009. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

etrials� is the registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and are used with permission.

Etrials Worldwide (MM) (NASDAQ:ETWC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024